PAREXEL INTERNATIONAL STRENGTHENS PRESENCE IN EUROPE
BOSTON, MA, October 17, 2001 — PAREXEL International Corporation (Nasdaq: PRXL) today announced the recent opening of additional offices in Belgium, Germany, and Romania, further expanding its ability to deliver comprehensive biopharmaceutical outsourcing services to clients worldwide.
Located in Brussels, Munich, and Bucharest, PAREXEL’s new Clinical Research Services in these locations will offer project management and clinical monitoring capabilities. The Munich office, situated within Germany’s major biotechnology center, is in close proximity to biotechnology and pharmaceutical companies, as well as important medical research sites and universities. The Belgian office, located near Brussels, is adjacent to many Belgian pharmaceutical companies as well as the Headquarters of the Commission of the European Communities. In addition, the Bucharest location offers an opportunity to meet PAREXEL’s clients’ needs for high-quality studies and will complement its capabilities within Central & Eastern Europe. Further expanding PAREXEL’s broad European presence, these facilities enable PAREXEL to address client requests for services locally in these geographic regions.
"These new offices have been opened to meet our clients’ needs for global expertise and knowledge of local country regulatory and clinical practices,” stated Carl Spalding, President and Chief Operating Officer. “The staff within these locations possess considerable expertise and a keen understanding of the local environment. With a large number of our employees located strategically throughout Europe, we believe that PAREXEL has the largest contract research organization presence on the European continent.”
Office locations and contact information:
Parc de Collines
Avenue Pasteur 9
T: +32 (10) 81 6969
F: +32 (10) 81 8275
PAREXEL Munchen GmbH
Landsberger Str. 6
Federal Republic of Germany
T: +49 (89) 500 592 30
F: +49 (89) 500 592 40
PAREXEL Nederland B.V.
Calea Dorobantilor, no. 134-138
Sector 1, 71232
T: +401 231 9759
F: +401 230 2807
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 54 locations throughout 35 countries around the world, and has over 4,640 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the period ended June 30, 2001, as filed with the Securities and Exchange Commission.